
Get exclusive money-saving offers and guides
Straight to your inbox
Posted
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
BARD1 Life Sciences Limited is a diagnostics & research business based in Australia. BARD1 Life Sciences shares (BD1) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. BARD1 Life Sciences has a trailing 12-month revenue of around $464,101..
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
Since the stock market crash in March caused by coronavirus, BARD1 Life Sciences's share price has had significant negative movement.
Its last market close was $0.028, which is 20.00% down on its pre-crash value of $0.035 and 47.37% up on the lowest point reached during the March crash when the shares fell as low as $0.019.
If you had bought $1,000 worth of BARD1 Life Sciences shares at the start of February 2020, those shares would have been worth $558.82 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $823.53.
52-week range | $0.019 - $0.052 |
---|---|
50-day moving average | $0.0267 |
200-day moving average | $0.0278 |
Target price | N/A |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.001 |
Standard brokerage - Australian shares
Competitive broker fees on Australian and international shares
Important: Share trading carries risk of capital loss.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of A$0.028 on 2020-10-22
1 week (2021-01-12) | -95.41% |
---|---|
1 month (2020-12-18) | -95.88% |
3 months (2020-10-19) | 12.00% |
6 months (2020-07-17) | -6.67% |
1 year (2020-01-17) | -97.25% |
---|---|
2 years (2019-01-18) | -95.91% |
3 years (2018-01-19) | -91.26% |
5 years (2016-01-19) | -96.79% |
Revenue TTM | $464,101 |
---|---|
Gross profit TTM | $-220,796 |
Return on assets TTM | -20.26% |
Return on equity TTM | -47.81% |
Profit margin | 0% |
Book value | 0.005 |
Market capitalisation | $62.3 million |
TTM: trailing 12 months
We're not expecting BARD1 Life Sciences to pay a dividend over the next 12 months.
BARD1 Life Sciences's shares were split on a 1:10 basis on 11 September 2008. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your BARD1 Life Sciences shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for BARD1 Life Sciences shares which in turn could have impacted BARD1 Life Sciences's share price.
Over the last 12 months, BARD1 Life Sciences's shares have ranged in value from as little as $0.019 up to $0.052. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while BARD1 Life Sciences's is -1.483. This would suggest that BARD1 Life Sciences's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, BARD1 Life Sciences has bucked the trend.
BARD1 Life Sciences Limited engages in the research and development of non-invasive diagnostic tests for early detection of cancer in Australia. The company offers hTERT test for diagnosis of bladder cancer, with the development-stage BARD1 autoantibody test for early detection of ovarian, breast and lung cancers; hTERT ICC test, an antibody-based immunocytochemistry stain that detects a component of telomerase; EXO-NET, a technology to capture and isolation of exosomes from any liquid biopsy sample; and BARD1 autoantibodies test to evaluate autoantibody panels and algorithms for detection of ovarian, breast and lung cancers. BARD1 Life Sciences Limited was incorporated in 1983 and is headquartered in South Perth, Australia.
Steps to owning and managing Vanguard Australian Fixed Interest Index ETF units.
Steps to owning and managing Vanguard Ethically Conscious Global Aggregate Bond Index (Hedged) ETF units.
Steps to owning and managing ETFS Morningstar Global Technology ETF units.
Steps to owning and managing BetaShares Global Quality Leaders (Currency Hedged) ETF units.
Steps to owning and managing ETFS ROBO Global Robotics and Automation ETF units.
Steps to owning and managing ETFS FANG+ ETF units.
Steps to owning and managing ETFS S&P Biotech ETF units.
Steps to owning and managing ETFS Reliance India Nifty 50 ETF units.
Steps to owning and managing BetaShares India Quality ETF units.